… Mary Bird Perkins recently hired multiple myeloma specialist Dr. Andy Dalovisio … out of state to get treatment,” Guba explains. “For … Clinic in Montana that treats Seab when he is … hundreds of others diagnosed with multiple myeloma covering travel, lodging and …

… half, we stop the drug, let them recover, … and then restart the drug again. Those infections … trial of teclistamab in patients with relapsed/refractory multiple myeloma … Tecvayli. Prescribing information. Janssen Pharmaceutical Companies; 2022. Accessed May …

… cell maturation antigen-directed antibody-drug conjugate, plus VRd in … are approved, regimen sequencing and treatment algorithm becomes an important conversation … in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. Nature Medicine …

… Mifepristone was developed by the French pharmaceutical company Roussel … specifically for medications that "treat serious or … 47;AIDS, cancer, and multiple myeloma—yet inexplicably pregnancy (which … the FDA required providers of the abortion pill to …

… release from the drug’s developer, Regeneron Pharmaceuticals, Inc.1 … CHMP to treat relapsed/refractory multiple myeloma. News release … FDA review for the treatment of relapsed/refractory multiple myeloma. News release. Regeneron Pharmaceuticals …

… drug, has long served as a cornerstone in the treatment of multiple myeloma … phase 1b clinical trial, conducted between September … “Optimizing the pharmacokinetics and pharmacodynamics of medications may be … area of therapeutic development.” REFERENCE Gabrail N …

Immuno-oncology Multiple myeloma (MM) is a complex disease … of interest. Qilu Pharmaceutical Co. Ltd. is hence developing a dual BCMA … antibody – QLS-4131 – for the treatment of MM. BioWorld Science Conferences …

… a precision oncology company developing novel diagnostic and therapeutic products … multiple myeloma, plasma cell malignancies and other blood cancers, and ultimately optimize treatment … a precision oncology company developing novel diagnostic and therapeutic …

… limited option Regeneron Pharmaceuticals has announced that … “In a clinical trial, linvoseltamab demonstrated compelling … multiple myeloma, a blood cancer that remains incurable despite treatment … advances. Regeneron is also pursuing its development …

… AENEID study published in Pharmaceuticals.1 With a median … 47;refractory multiple myeloma in the phase 3 IKEMA trial (NCT03275285).2 … PFS, OS, time to next treatment (TTNT), and safety. Investigators … , real-life AENEID study. Pharmaceuticals (Basel). 2025;18(4 …